ADVANCING


THE LUNG CANCER TREATMENT LANDSCAPE



Sunday 11 September 2022 13.00-14.30 CEST



Paris Expo Porte de Versailles Paris, France





Dear Sir/Madam,

We are delighted to invite you to the Amgen-sponsored symposium to be held at the European Society for Medical Oncology (ESMO) 2022 congress, entitled: 'Advancing the lung cancer treatment landscape: novel targets for improved patient care'.

Click the video below to watch the symposium Chair, Professor Fabrice Barlesi, introduce the Faculty and the topics to be discussed in this 90-minute session exploring the evolving field of lung cancer treatment.

The symposium will conclude with an engaging 20-minute panel discussion with an audience Q&A.





PROGRAMME

Welcome and introduction Fabrice Barlesi, France

Non-squamous versus squamous NSCLC: actionable and emerging targets

Jürgen Wolf, Germany

Towards a new era of biomarker-driven therapy in SCLC **Noemi Reguart**, **Spain**

Expanding treatment opportunities in SCLC: targeting DLL3

Stéphane Champiat, France

Panel discussion and Q&A **All**

Please come and join us in 7.3.G- Grenoble Auditorium Hall 7, Level 7.3 at 13.00 CEST for this engaging and informative session.

Best regards,

Global Medical Team, Oncology



Disclaimer: This message and any attachments are solely for the intended recipient and may contain confidential or privileged information. If you are not the intended recipient, any disclosure, copying, use, or distribution of the information included in this message and any attachments is prohibited.

If you have received this communication in error, please notify us by replying to this email and permanently delete this message and any attachments.

Thank you.

Unsubscribe here



Oncology

SC-ELMAC-CP-00148
Amgen Europe GmbH
6343 Rotkreuz, Switzerland
Date of preparation: August 2022
www.amgen.com © 2022 Amgen Inc.
All rights reserved.